Brief: Spectral Medical Announces Positive Results Of Euphas-2 Clinical Trial Evaluating Pmx In Critically Ill Endotoxemic Septic Shock Patients
18/04/2023 13:08
April 18 (Reuters) - Spectral Medical Inc EDT.TO :
* SPECTRAL MEDICAL ANNOUNCES POSITIVE RESULTS OF EUPHAS-2
CLINICAL
TRIAL EVALUATING PMX IN CRITICALLY ILL ENDOTOXEMIC SEPTIC SHOCK
PATIENTS
* SPECTRAL MEDICAL - 28-DAY MORTALITY OF 36% FOR PATIENTS
UNDERGOING PMX HEMOADSORPTION VS75% PREDICTED BY SAPS II
MORTALITY ESTIMATION TOOL IN STUDY
Source text for Eikon: ID:nGNXfW3Mb
Further company coverage: EDT.TO
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%